Omeros Corporation
http://www.omeros.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Omeros Corporation
Finance Watch: 2020 Is Four Biopharma IPOs Away From Matching 2019
With 46 initial public offerings in the US by drug developers so far – including recent launches by Kymera, Inhibrx and Harmony – 2020 will easily beat last year’s 50 IPOs. In follow-on offerings and VC deals, newly public Schrodinger raised $346.5m and Tango’s $50m equity financing.
Scipher Hopes IBD Alliance With Galapagos Is The First Of Many
Focused primarily on developing diagnostic tests to determine whether patients will respond to a drug, Scipher is also using the data from its artificial intelligence process to drive R&D partnerships with drug developers.
Tech Transfer Roundup: Hoth Teams With VCU On Therapy To Block COVID-19 Replication
Pandemic-related collaborations between Hoth/VCU; Sorrento/Mt. Sinai Health; Audax/Northeastern U.; Alkido/U. of Maryland, Baltimore; Active Motif/Hisun BioRay/Fudan U. and more.
Scrip Asks…What Does 2020 Hold For Biopharma? Part 1: Therapeutic Advances
Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule